Therefore, TIGIT represents a promising target for immunotherapy in patients with GBM, and ongoing clinical trials are evaluating anti-TIGIT combined with anti-PD-1 antibody treatment for recurrent GBM (NCT04656535). The gene discussed is PDCD1; the disease is glioblastoma.